Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Familial dysfibrinogenemia is a coagulation disorder characterized by a bleeding tendency due to a functional anomaly of circulating fibrinogen.
FGA encodes fibrinogen alpha chain (866 aa). Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Highest expression in Liver (5,498 TPM) and Stomach (12.4 TPM).
Familial dysfibrinogenemia is associated with mutations in the FGA gene on chromosome 4.
The FGA protein participates in FGAR + L-Glutamine + ATP + H2O = FGAM + L-Glutamate + ADP + Pi pathway.
FGA is classified as a druggable target (Cell Surface, Druggable Genome, External Side Of Plasma Membrane, and Fibrinogen categories) with score 3.2.
FGB encodes fibrinogen beta chain (491 aa). Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Highest expression in Liver (7,352 TPM) and Kidney Cortex (6.8 TPM).
Familial dysfibrinogenemia is associated with mutations in the FGB gene on chromosome 4.
Genetic testing for FGA, FGB, FGG is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for familial dysfibrinogenemia has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered.
55 publications have been identified in PubMed for familial dysfibrinogenemia. Research spans Case Report / Case Series (31%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 31% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 9:17 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
The FGB protein participates in fibrinogen - fibrin monomer + 2 fibrinopeptide A + 2 fibrinopeptide B pathway.
FGB is classified as a druggable target (Cell Surface, Druggable Genome, External Side Of Plasma Membrane, and Fibrinogen categories) with score 3.1.
FGG encodes fibrinogen gamma chain (453 aa). Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. Highest expression in Liver (5,968 TPM) and Lung (10.5 TPM).
Familial dysfibrinogenemia is associated with mutations in the FGG gene on chromosome 4.
The FGG protein participates in fibrinogen - fibrin monomer + 2 fibrinopeptide A + 2 fibrinopeptide B pathway.
FGG is classified as a druggable target (Cell Surface, Druggable Genome, External Side Of Plasma Membrane, and Fibrinogen categories) with score 4.4.
10 |
18% |
Disease patterns and progression | 9 | 16% |
Laboratory research | 7 | 13% |
Other research | 4 | 7% |
Testing and diagnosis research | 4 | 7% |
Clinical study results | 3 | 5% |
New treatment approaches | 1 | 2% |
Sun S (2026). [PMID: 41641643](https://pubmed.ncbi.nlm.nih.gov/41641643/). *Haematologica*. [Basic Science / Preclinical]
Wang A (2026). [PMID: 42081361](https://pubmed.ncbi.nlm.nih.gov/42081361/). *J Vis Exp*. [Case Report / Case Series]
Huang J (2026). [PMID: 41344552](https://pubmed.ncbi.nlm.nih.gov/41344552/). *Clin Biochem*. [Basic Science / Preclinical]
Berkowitz C (2026). [PMID: 41658980](https://pubmed.ncbi.nlm.nih.gov/41658980/). *Res Pract Thromb Haemost*. [Epidemiology / Natural History]
Mao X (2026). [PMID: 41933331](https://pubmed.ncbi.nlm.nih.gov/41933331/). *Thromb J*. [Case Report / Case Series]
Suzuki A (2026). [PMID: 42027313](https://pubmed.ncbi.nlm.nih.gov/42027313/). *Res Pract Thromb Haemost*. [Diagnostic / Biomarker]
Nóbrega T (2026). [PMID: 40879865](https://pubmed.ncbi.nlm.nih.gov/40879865/). *J Thromb Thrombolysis*. [Review / Meta-Analysis]
Mahurkar S (2026). [PMID: 42182551](https://pubmed.ncbi.nlm.nih.gov/42182551/). *Cureus*. [Other]
Bor MV (2026). [PMID: 41664865](https://pubmed.ncbi.nlm.nih.gov/41664865/). *Blood Coagul Fibrinolysis*. [Case Report / Case Series]
Cheng XL (2026). [PMID: 41983153](https://pubmed.ncbi.nlm.nih.gov/41983153/). *J Hematol*. [Basic Science / Preclinical]